S-1/A: Cardiff Lexington Files S-1/A for Nasdaq Uplisting & $6M Offering

Cardiff Lexington Corporation filed an S-1/A, detailing a proposed 1.2 million share common stock offering contingent on a Nasdaq uplisting, alongside recent financial losses and ongoing liquidity concerns.

Summary

• Cardiff Lexington Corporation is a healthcare holding company focused on acquiring and building niche healthcare clinics, primarily in orthopedics, spine care, and pain management, and also owns a real estate company, Edge View Properties, Inc.
• The company is offering 1,200,000 shares of common stock at an assumed public offering price of $5.00 per share, with net proceeds estimated at $4.9 million (or $5.7 million if the over-allotment option is fully exercised).
• The closing of this offering is contingent upon the company's common stock uplisting to The Nasdaq Capital Market under the symbol CDIX.
• For the nine months ended September 30, 2025, total revenue increased by 70.18% to $8,763,314 from $5,149,416 in the prior year period, though a significant portion of this increase is due to accounting adjustments.
• The company reported a net loss of $2,821,471 for the nine months ended September 30, 2025, an increase from the $2,392,657 net loss for the same period in 2024.
• For the year ended December 31, 2024, the company incurred a net loss of $3,302,999, a significant decline from a net income of $3,028,394 in 2023.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report, citing recurring operating losses and negative cash flows.
• Management believes $5 million to $10 million in additional outside capital is necessary to execute its business plan and acquisition strategy, with up to $10 million in cash required if sellers are unwilling to accept notes and equity.
• The company's healthcare business primarily focuses on plaintiff-related care for uninsured patients, leading to an extended accounts receivable collection period of 18 to 24 months.
• The settlement realization rate for accounts receivable decreased from a historical 49% to 44% for the nine months ended September 30, 2024, and further to 42% as of September 30, 2025, due to efforts to accelerate cash settlements by accepting lower amounts.
• Material weaknesses in internal control over financial reporting have been identified, including a lack of formal documentation, proper segregation of duties, and sufficient resources for complex debt and equity transactions.
• The company implemented a 1-for-3 reverse stock split on January 12, 2026, reducing outstanding common stock from 41,152,612 to 13,718,365 shares.
• Alex Cunningham, CEO, converted $2,365,242 of deferred compensation into 556,528 shares of common stock on January 29, 2026.
• The company's line of credit with DML HC Series, LLC was increased to a maximum advance amount of $23,000,000 on October 1, 2025.
• Two stockholders, including the CEO and former Chairman, will collectively hold approximately 68% of the total voting power after the offering.
• New investors in this offering will experience immediate and substantial dilution of $4.58 per share based on the assumed public offering price of $5.00 per share.
• The company has no current plans to pay cash dividends on its common stock for the foreseeable future.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to recurring losses, significant accumulated deficit, a going concern warning from auditors, and identified material weaknesses in internal controls. While revenue growth is noted, it's overshadowed by declining settlement rates and substantial dilution for new investors.

Positives

• Total revenue for the nine months ended September 30, 2025, increased by 70.18% to $8,763,314 compared to the same period in 2024, driven by increased office visits and surgical procedures.
• Gross profit for the nine months ended September 30, 2025, significantly increased by 126.17% to $5,445,371, and gross margin improved from 46.76% to 62.14%.
• The company's line of credit was increased to $23,000,000, providing enhanced liquidity and capital for operations and potential acquisitions.
• Management has identified significant opportunities for organic growth at existing healthcare facilities, which are currently operating at 35% capacity.
• The company has a disciplined strategy for strategic acquisitions in the fragmented healthcare market, focusing on outpatient Orthopedic Surgery Centers and related Clinics in 18 identified states.
• The company's healthcare business model, focusing on plaintiff-related care, partially insulates it from declining reimbursement programs from Medicare/Medicaid and traditional health insurance companies.
• The company has a strong track record of efficient revenue cycle management through managed care contracting, billing, coding, collection, and compliance processes.
• The company has made significant investments in scalable technology systems to improve clinical results, client metrics, and reduce patient care costs.
• The company's management team possesses extensive experience in executive, investment, and operational roles within small and middle-market healthcare companies, providing a competitive advantage in acquisitions.

Negatives

• The company has sustained recurring operating losses since its inception and has an accumulated deficit of $76,533,799 as of September 30, 2025.
• Net loss increased by 17.92% to $2,821,471 for the nine months ended September 30, 2025, compared to the same period in 2024.
• Cash decreased significantly from $1,188,185 at December 31, 2024, to $232,033 at September 30, 2025.
• The company had negative cash flow from operating activities of $2,463,300 for the nine months ended September 30, 2025.
• The extended accounts receivable collection period (18-24 months) creates significant liquidity and cash flow constraints, increases exposure to bad debt, and necessitates reliance on external financing.
• The settlement realization rate for accounts receivable has declined from a historical 49% to 42% as of September 30, 2025, indicating lower cash recovery per billed charge.
• The company lacks systematic processes and resources to support the aging of its accounts receivables, leading to inefficiencies and higher operational costs, with significant expenditures expected to remedy this.
• Total revenue decreased by 30.23% for the year ended December 31, 2024, compared to 2023, primarily due to lower settlement realization rates from surgical procedures, an increase in lower-revenue pain management treatments, and negative impacts from hurricane season in Florida.
• Gross profit decreased by 46.60% for the year ended December 31, 2024, compared to 2023, with gross margin falling from 69.96% to 53.55%.
• Interest expense increased significantly to $4,594,714 for the nine months ended September 30, 2025, from $1,803,657 in the prior year period, primarily due to increased fees on the line of credit.
• The company's real estate segment (Edge View Properties) has not generated any revenues to date, except for the sale of three parcels of land in 2021, and management expects to eventually sell the property without development plans.
• The company has no current plans to pay cash dividends on its common stock for the foreseeable future.

Risks

• The report of the independent registered public accounting firm included a going concern explanatory paragraph, raising substantial doubt about the company's ability to continue operations.
• The typical accounts receivable collection lifecycle of 18 to 24 months creates liquidity and cash flow constraints, increases exposure to bad debt, and necessitates dependence on external financing.
• Lack of systematic processes and resources to support the aging of accounts receivables can lead to inefficiencies, higher operational costs, and potential inaccuracies in financial reporting.
• The company's acquisition strategy exposes it to substantial risks, including failure to identify material problems during due diligence, over-paying for assets, and difficulties in integrating acquired businesses.
• Failure to manage the company's growing and changing business could have a material adverse effect on its business, prospects, financial condition, and results of operations.
• Competition for acquisition targets may force the company to acquire businesses at sub-optimal prices or forego attractive opportunities.
• Inability to successfully fund acquisitions due to unavailability of equity or debt financing on acceptable terms could impede the implementation of the acquisition strategy.
• Future success is dependent on the management teams of its businesses, and the loss of key personnel could materially adversely affect financial condition and results of operations.
• Potential conflicts of interest may arise if the company engages in business transactions with target businesses that have relationships with its executive officers, directors, or their affiliates.
• The company may be deemed an investment company under the Investment Company Act if it ceases to control and operate its businesses or engages in certain investment-related activities.
• Material weaknesses in internal control over financial reporting have been identified, which could lead to inaccurate financial reporting and fraud.
• The ability to grow the healthcare business through organic expansion is dependent on many factors, including capacity, occupancy, and the availability of suitable sites for new or modified facilities.
• Changes to payment rates or methods of third-party payors, including government healthcare programs, or changes to the payor mix, could adversely affect operating margins and revenues.
• An increase in uninsured or underinsured patients or deterioration in the collectability of their accounts could harm results of operations.
• Failure to timely or accurately bill for services could negatively impact net revenue and cash flow.
• The company's healthcare facilities face intense competition for patients from other healthcare providers, some with greater resources or tax advantages.
• Performance depends on the ability to recruit and retain quality physicians, nurses, and medical support staff, and staffing shortages could increase labor costs or limit services.
• Failure to comply with extensive healthcare laws and government regulations could result in civil or criminal penalties, or require significant operational changes.
• Loss of accreditation for existing facilities or failure to receive accreditation for new facilities could render them ineligible for Medicare or Medicaid reimbursement.
• The company could be subject to lawsuits, including medical malpractice and professional liability claims, which could harm business value and reputation.
• The real estate business is subject to demand fluctuations, adverse weather conditions, natural disasters, and unforeseen planning or environmental issues.
• A decrease in the market value of real estate investments could negatively impact results of operations.
• Changes in tax laws, taxes, or fees may increase the cost of development or sale of real estate property.
• The company may incur environmental liabilities with respect to its real estate assets, including remediation costs for hazardous substances.
• Uninsured losses relating to real property or excessively expensive insurance premiums may adversely affect stock value.
• There has been limited trading in the common stock, and an active market may not develop, leading to high volatility and difficulty in reselling shares.
• The market price of common stock may be highly volatile due to various factors, including speculative trading and lack of profits.
• The company may not be able to maintain its listing on Nasdaq, which could impair stockholders' ability to buy and sell common stock.
• Two stockholders own a significant percentage of voting securities (approximately 68%), which could reduce the ability of minority stockholders to effect corporate actions.
• Management has broad discretion over the use of net proceeds from the offering, which may not yield significant returns.
• Future issuances of common stock or convertible securities, or the expiration of lock-up agreements, could cause the market price to decline and dilute existing holdings.
• Rule 144 sales in the future may have a depressive effect on the stock price.
• Future issuances of debt or preferred stock could rank senior to common stock, adversely affecting returns.
• If shares become subject to penny stock rules, it would become more difficult to trade them.
• Lack of research reports from securities industry analysts could negatively affect market price and trading volume.
• Anti-takeover provisions in charter documents and Nevada law could make an acquisition more difficult and limit attempts by stockholders to replace management.
• Investment in the company may involve complex tax implications, and unanticipated changes in tax rates or adverse audit outcomes could affect financial condition.

Future Outlook

The company intends to use the net proceeds from the offering for debt repayment, working capital, general corporate purposes, and future acquisitions. Management believes current working capital and expected additional financing should be sufficient to fund operations for at least one year, but additional funds ranging from $5 million to $10 million are required for continued operations and to execute its acquisition strategy. The company will continue to evaluate its settlement realization rates monthly and update estimates quarterly. It expects to make significant expenditures to implement enhanced processes for managing accounts receivables. The company has no current plans to pay cash dividends for the foreseeable future.

Management Comments

• Management believes, based on our operating plan, that current working capital and current and expected additional financing should be sufficient to fund operations and satisfy our obligations as they come due for at least one year.
• Management believes that the amount of outside additional capital necessary to execute our business plan on the low end (assuming target company sellers accept a significant portion of the purchase price in the form of seller notes or our equity or equity in one of our subsidiaries) ranges between $5 million to $10 million.
• If, and to the extent, that sellers are unwilling to accept a significant portion of the purchase price in seller notes and equity, then the cash required to execute our business plan could be as much as $10 million.
• Management does not currently have any plans to develop this property and expects to eventually sell the property (Edge View Properties).
• Management estimates that the twelve facilities are operating at 35% capacity as of September 30, 2025, indicating an opportunity for organic growth.
• We believe that our operating infrastructure enables us to provide attractive opportunities for our providers to enhance their skills through extensive clinical and leadership development programs.

Industry Context

StockSavvy.ai notes that Cardiff Lexington's focus on acquiring middle-market niche healthcare clinics, particularly in orthopedics, spine care, and pain management, aligns with a broader trend of consolidation in specialized healthcare sectors. The reliance on plaintiff-related care for uninsured patients, while insulating the company from traditional Medicare/Medicaid reimbursement pressures, introduces unique challenges related to extended accounts receivable cycles and settlement realization rates, which are not typical for general healthcare providers. The company's strategy to retain personal injury practice accounts receivable rather than selling at deep discounts is an attempt to capture long-term income, a differentiator in this specific market segment. The identified material weaknesses in internal controls and the going concern warning are significant red flags that could deter investors, especially when compared to more established, financially stable players in the healthcare M&A space.

Comparison to Industry Standards

• The accounts receivable collection cycle of 18 to 24 months is significantly longer than the typical 30-90 day cycles seen in most product or service businesses, including many traditional healthcare providers, indicating a unique operational challenge due to the plaintiff-related care model.
• The declining settlement realization rate from 49% historically to 42% as of September 30, 2025, suggests a lower effective revenue capture per billed charge compared to previous periods, which could impact profitability more severely than competitors with more stable or higher reimbursement rates.
• The company's operating capacity of 35% at its twelve facilities as of September 30, 2025, indicates substantial underutilization compared to industry benchmarks for efficient clinic operations, which typically aim for much higher occupancy rates to maximize fixed asset returns.
• The presence of a 'going concern' explanatory paragraph from independent auditors is a critical indicator of financial distress, a condition that would typically place the company significantly below industry standards for financial stability and investor confidence, unlike well-capitalized healthcare holding companies such as HCA Healthcare or Tenet Healthcare, which generally demonstrate robust financial health and strong liquidity.
• The identified material weaknesses in internal control over financial reporting are a serious governance concern, contrasting sharply with the robust internal control frameworks expected of publicly traded companies and industry leaders, which are crucial for accurate financial reporting and fraud prevention.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition, or operating results.
• The company is subject to claims and suits in the ordinary course of business, including those arising from services provided, personal injury claims, professional liability claims, billing and marketing practices, employment disputes, and contractual claims.
• Physicians, hospitals, and other healthcare participants are subject to an increasing number of medical malpractice lawsuits and related legal theories.
• The company may become exposed to legal claims for the activities of an acquired business prior to the acquisition.

Related Party Transactions

• Short-term advances from Daniel Thompson, former Chairman of the Board, totaling $120,997 as of December 31, 2023, were fully repaid during the year ended December 31, 2024.
• The company assumed amounts due to previous owners who are current managers of Edge View Properties, Inc. in connection with its acquisition on July 16, 2014; the balance of these amounts is $4,979 as of September 30, 2025, and December 31, 2024, which are due on demand and do not bear interest.
• Alex Cunningham, Chief Executive Officer, converted $2,365,242 of deferred compensation into 556,528 shares of common stock on January 29, 2026.
• Alex Cunningham's employment agreement, effective January 1, 2025, entitles him to an initial base salary of $885,000 per year, annual bonuses, and automatic salary increases based on company performance and uplisting to Nasdaq. Past due amounts owed to Mr. Cunningham accrue interest at 5% quarterly.
• Daniel Thompson's employment agreement, amended January 1, 2025, entitled him to a base salary of $700,000 for calendar year 2025 and performance bonuses. Past due amounts owed to Mr. Thompson accrue interest at 5% quarterly. His employment is expected to terminate on December 31, 2025, with subsequent annual compensation payments.
• The company issued a twelve-month convertible promissory note in the principal amount of $5,000 to the CEO on August 25, 2023, which was paid in full in August 2024.
• The company issued 62,500 shares of series I preferred stock to Daniel R. Thompson and Alex Cunningham on January 19, 2024, for $250,000 bonus compensation for fiscal year 2023.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the public offering and future equity issuances. The going concern warning and recurring losses pose a high risk of investment loss. The concentration of voting power with two major stockholders could limit minority shareholder influence. Nasdaq uplisting, if successful, could improve liquidity and visibility.
• **Employees**: The company's growth strategy through acquisitions and organic expansion could create new opportunities. Equity incentive plans aim to align employee interests with stockholders. However, staffing shortages in the healthcare segment could lead to increased labor costs or service limitations.
• **Customers (Patients)**: The focus on plaintiff-related care for uninsured patients provides a specific service, but the extended accounts receivable collection period could indirectly affect the company's ability to invest in and expand services if liquidity is constrained.
• **Suppliers/Creditors**: The company's reliance on a line of credit and other debt, coupled with recurring losses and a going concern warning, indicates elevated credit risk. Extended accounts receivable cycles could impact the company's ability to make timely payments to suppliers.
• **Management**: The management team is heavily involved in the acquisition strategy and day-to-day operations. Their compensation is tied to performance and equity incentives. The identified material weaknesses in internal controls place additional responsibility on management to implement effective remediation.

Next Steps

• Complete the proposed public offering of 1,200,000 shares of common stock.
• Achieve uplisting of common stock to The Nasdaq Capital Market.
• Repay certain debt obligations using net proceeds from the offering, including a $85,000 balance on a settlement promissory note and potentially $80,000 on convertible promissory notes.
• Implement enhanced practices to better capture and manage the aging of accounts receivables, which is expected to take 18 to 24 months and require significant resources.
• Continue efforts to remedy identified material weaknesses in internal control over financial reporting.
• Pursue organic growth opportunities at existing healthcare facilities, which are currently operating at 35% capacity.
• Explore and execute strategic acquisitions of outpatient Orthopedic Surgery Centers and related Clinics in identified states.
• Continue to evaluate and update the estimate of settlement realization rates for accounts receivable on a quarterly basis.
• Alex Cunningham's base salary is scheduled to increase by a minimum of 10% per year beginning January 1, 2026, and by an additional $100,000 upon successful Nasdaq listing and $4 million capital raise.
• Matthew Shafer's restricted stock award for 8,334 shares of common stock will vest in full on December 11, 2026.
• Independent directors' stock options for 16,667 shares of common stock will vest quarterly over one year commencing January 1, 2026.
• Daniel Thompson's employment agreement is expected to terminate on December 31, 2025, with annual compensation payments scheduled for 2026, 2027, and 2028.

Key Dates

Recommendation

The filing presents a highly speculative investment. The company has a history of recurring operating losses, a significant accumulated deficit, and a 'going concern' warning from its independent auditors, indicating substantial doubt about its ability to continue operations. While revenue growth is reported for the nine months ended September 30, 2025, it's partially attributed to accounting adjustments, and the full-year 2024 revenue declined significantly, swinging from a net income to a substantial net loss. The declining settlement realization rate for accounts receivable and identified material weaknesses in internal controls further compound financial risks. The proposed public offering, while aiming to raise capital, will result in immediate and substantial dilution for new investors. Given these severe financial and operational challenges, a seasoned investor or institution would likely recommend selling or avoiding this stock due to the high risk of capital loss and fundamental instability.

Keywords

Healthcare, Orthopedics, Pain Management, Spine Care, Medical Clinics, Acquisition Strategy, SEC Filing, S-1/A, Nasdaq Uplisting, Common Stock Offering, Accounts Receivable, Going Concern, Liquidity, Financial Performance, Nevada Corporation, Real Estate, CDIX